Literature DB >> 26636902

RSV vaccine use--the missing data.

Simon B Drysdale1,2, Charles J Sande1, Christopher A Green1, Andrew J Pollard1,2.   

Abstract

Respiratory syncytial virus (RSV) infection is the most important cause of hospitalization in infants and is one of the leading global causes of infant mortality and as such its prevention through vaccination is a public health priority. While essential for the successful implementation of vaccine programs, there remains a paucity of data on the epidemiology of the virus in different settings and age groups and limited knowledge about virus transmission and the health-care costs of the disease. Such data are now needed to populate health economic models and to inform optimal approaches to disease control through vaccination.

Entities:  

Keywords:  RSV; cost–effectiveness mode; epidemiology; health economics; respiratory syncytial virus; vaccine; viral transmission

Mesh:

Substances:

Year:  2015        PMID: 26636902     DOI: 10.1586/14760584.2016.1114419

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  9 in total

1.  Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England.

Authors:  Deborah Cromer; Albert Jan van Hoek; Anthony T Newall; Andrew J Pollard; Mark Jit
Journal:  Lancet Public Health       Date:  2017-07-31

2.  The contribution of child, family and health service factors to respiratory syncytial virus (RSV) hospital admissions in the first 3 years of life: birth cohort study in Scotland, 2009 to 2015.

Authors:  Pia Hardelid; Maximiliane Verfuerden; Jim McMenamin; Rosalind L Smyth; Ruth Gilbert
Journal:  Euro Surveill       Date:  2019-01

3.  Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types.

Authors:  Lydia J Atherton; Patricia A Jorquera; Abhijeet A Bakre; Ralph A Tripp
Journal:  Front Immunol       Date:  2019-10-09       Impact factor: 7.561

Review 4.  Whither vaccines?

Authors:  Charlene M C Rodrigues; Marta V Pinto; Manish Sadarangani; Stanley A Plotkin
Journal:  J Infect       Date:  2017-06       Impact factor: 6.072

5.  Extracellular amoebal-vesicles: potential transmission vehicles for respiratory viruses.

Authors:  Rafik Dey; Melanie A Folkins; Nicholas J Ashbolt
Journal:  NPJ Biofilms Microbiomes       Date:  2021-03-17       Impact factor: 7.290

6.  Potential Cost-Effectiveness of RSV Vaccination of Infants and Pregnant Women in Turkey: An Illustration Based on Bursa Data.

Authors:  Koen B Pouwels; Sefika E Bozdemir; Selen Yegenoglu; Solmaz Celebi; E David McIntosh; Serhat Unal; Maarten J Postma; Mustafa Hacimustafaoglu
Journal:  PLoS One       Date:  2016-09-30       Impact factor: 3.240

7.  Human respiratory syncytial virus and hospitalization in young children in Italy.

Authors:  Parvanè Kuhdari; Federica Brosio; Cristina Malaventura; Armando Stefanati; Andrea Orsi; Giancarlo Icardi; Giovanni Gabutti
Journal:  Ital J Pediatr       Date:  2018-05-04       Impact factor: 2.638

8.  Paediatric Virology and respiratory syncytial virus: An interview with Honorary Senior Lecturer in Paediatric Infectious Diseases Dr Simon B. Drysdale (St. George's, University of London, UK).

Authors:  Ioannis N Mammas; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2019-08-28       Impact factor: 2.447

9.  Community factors associated with local epidemic timing of respiratory syncytial virus: A spatiotemporal modeling study.

Authors:  Zhe Zheng; Virginia E Pitzer; Joshua L Warren; Daniel M Weinberger
Journal:  Sci Adv       Date:  2021-06-23       Impact factor: 14.957

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.